Banco Santander S.A. Cuts Position in Illumina, Inc. (NASDAQ:ILMN)

Banco Santander S.A. reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 18.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,474 shares of the life sciences company’s stock after selling 4,950 shares during the period. Banco Santander S.A.’s holdings in Illumina were worth $2,346,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Truist Financial Corp grew its holdings in shares of Illumina by 4.3% in the fourth quarter. Truist Financial Corp now owns 60,101 shares of the life sciences company’s stock valued at $8,369,000 after purchasing an additional 2,462 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Illumina by 78.1% during the fourth quarter. Russell Investments Group Ltd. now owns 69,646 shares of the life sciences company’s stock worth $9,725,000 after acquiring an additional 30,538 shares during the period. Intact Investment Management Inc. acquired a new stake in shares of Illumina in the fourth quarter valued at $418,000. Victory Capital Management Inc. boosted its holdings in Illumina by 5.9% in the fourth quarter. Victory Capital Management Inc. now owns 122,743 shares of the life sciences company’s stock valued at $17,091,000 after purchasing an additional 6,827 shares during the period. Finally, Iyo Bank Ltd. acquired a new position in Illumina during the 4th quarter worth $766,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. StockNews.com started coverage on shares of Illumina in a research note on Thursday. They issued a “buy” rating for the company. JPMorgan Chase & Co. lowered their target price on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target on the stock in a research note on Wednesday, August 14th. Daiwa America raised Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Evercore ISI dropped their price objective on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a report on Tuesday, June 11th. One analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $151.05.

Illumina Price Performance

Shares of Illumina stock traded up $2.08 during trading on Thursday, reaching $133.78. The company’s stock had a trading volume of 1,225,621 shares, compared to its average volume of 2,086,404. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $171.50. The company has a market capitalization of $21.31 billion, a P/E ratio of -16.41 and a beta of 1.15. The business has a 50 day moving average price of $118.30 and a 200-day moving average price of $121.76.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the firm earned $0.32 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Illumina, Inc. will post 1.5 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.